IL327175A - תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv - Google Patents

תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv

Info

Publication number
IL327175A
IL327175A IL327175A IL32717526A IL327175A IL 327175 A IL327175 A IL 327175A IL 327175 A IL327175 A IL 327175A IL 32717526 A IL32717526 A IL 32717526A IL 327175 A IL327175 A IL 327175A
Authority
IL
Israel
Prior art keywords
subject
pharmaceutical composition
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL327175A
Other languages
English (en)
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68318947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL327175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of IL327175A publication Critical patent/IL327175A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL327175A 2018-10-04 2019-10-03 תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv IL327175A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (1)

Publication Number Publication Date
IL327175A true IL327175A (he) 2026-05-01

Family

ID=68318947

Family Applications (2)

Application Number Title Priority Date Filing Date
IL327175A IL327175A (he) 2018-10-04 2019-10-03 תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv
IL281965A IL281965B2 (he) 2018-10-04 2021-04-01 תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL281965A IL281965B2 (he) 2018-10-04 2021-04-01 תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv

Country Status (13)

Country Link
US (1) US11207299B2 (he)
EP (1) EP3860594B1 (he)
JP (2) JP7524167B2 (he)
KR (1) KR102902972B1 (he)
CN (1) CN113286587A (he)
AU (1) AU2019354784B2 (he)
BR (1) BR112021006132A2 (he)
CA (1) CA3114434A1 (he)
ES (1) ES3057657T3 (he)
IL (2) IL327175A (he)
MA (1) MA53817A (he)
MX (1) MX2021003606A (he)
WO (1) WO2020072814A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo

Also Published As

Publication number Publication date
CA3114434A1 (en) 2020-04-09
MX2021003606A (es) 2021-08-16
ES3057657T3 (en) 2026-03-03
KR102902972B1 (ko) 2025-12-22
KR20210081338A (ko) 2021-07-01
AU2019354784A1 (en) 2021-04-15
US11207299B2 (en) 2021-12-28
IL281965B2 (he) 2026-08-01
AU2019354784B2 (en) 2025-07-10
EP3860594A1 (en) 2021-08-11
JP2022514152A (ja) 2022-02-10
MA53817A (fr) 2021-08-11
JP2024133735A (ja) 2024-10-02
IL281965A (he) 2021-05-31
US20200147050A1 (en) 2020-05-14
WO2020072814A1 (en) 2020-04-09
BR112021006132A2 (pt) 2021-07-20
EP3860594B1 (en) 2025-10-01
JP7524167B2 (ja) 2024-07-29
IL281965B1 (he) 2026-04-01
CN113286587A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
SG11202104705RA (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
PT3600309T (pt) Combinações terapêuticas para o tratamento de doenças hepáticas
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
IL279260A (he) מעכבי kdm1a לטיפול במחלות
EP3221321A4 (en) Fused bicyclic compounds for the treatment of disease
EP3140291A4 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
IL281965A (he) תרכובות ביפניל סולפונאמיד לטיפול במחלות קולגן מסוג iv
HUE039288T2 (hu) Pirrolidin GPR40 modulatorok betegségeknek, mint például diabétesz kezelésére
EP4744733A2 (en) Biphenylsulfonamide compounds for the treatment of kidney diseases or disorders
SG11202103253YA (en) Therapeutic compounds
ZA201807509B (en) Di-substituted pyrazole compounds for the treatment of diseases
SI3210973T1 (sl) Heteroarilne spojine za zdravljenje oftalmičnih bolezni
GB201805100D0 (en) Treatment of sarcopenic diseases
PL3761982T3 (pl) Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych
GB201808150D0 (en) Therapeutic compounds
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
ME03056B (me) Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac
EP3261635A4 (en) Compounds for treating ocular diseases
HK40012876A (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
HK40061035A (en) Novel compounds for the treatment of respiratory diseases
HK40049516A (en) Kdm1a inhibitors for the treatment of disease
GB201805099D0 (en) Treatment of osteoporotic diseases